Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.

Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.

Oxovanadium-based inhibitors can drive redox-sensitive cytotoxicity in neuroblastoma cells and synergise strongly with buthionine sulfoximine.

Buthionine sulfoximine-induced cytostasis does not correlate with glutathione depletion.

The pro-oxidant buthionine sulfoximine (BSO) reduces tumor growth of implanted Lewis lung carcinoma in mice associated with increased protein carbonyl, tubulin abundance, and aminopeptidase activity.

Depletion of a discrete nuclear glutathione pool by oxidative stress, but not by buthionine sulfoximine. Correlation with enhanced alkylating agent cytotoxicity to human melanoma cells in vitro.

Pretreatment with buthionine sulfoximine enhanced uptake and retention of BSH in brain tumor.

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.

or buthionine sulfoximine on teratogenicity of 5-fluorouracil in mice.

The effect of in vivo glutathione depletion with buthionine sulfoximine on rat embryo development.

Heterogeneity in response to treatment with buthionine sulfoximine or interferon in human malignant glioma cells.

Effects of buthionine sulfoximine and diethyl maleate on glutathione turnover in the channel catfish.

Thermochemotherapy for B16 melanoma: combination therapy of hyperthermia, melphalan, and CCNU in mice.

Selenite-induced inhibition of colony formation by buthionine sulfoximine-sensitive and resistant cell lines.

Lens GSH depletion and electrolyte changes preceding cataracts induced by buthionine sulfoximine in suckling mice.

Interaction of buthionine sulfoximine and the stabilization of DNA-topoisomerase II complexes by doxorubicin.

Protective Effect of Tempol on Buthionine Sulfoximine-Induced Mitochondrial Impairment in Hippocampal Derived HT22 Cells.

3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.

Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion.

Enhanced in vitro cytotoxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea or buthionine sulfoximine combined with a reactive oxygen-generating enzyme immunotoxin.

Progressive modifications of mouse lens crystallins in cataracts induced by buthionine sulfoximine.

The effects of buthionine sulfoximine treatment on diaphragm contractility and SERCA pump function in adult and middle aged rats.

Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.

The deleterious effect of buthionine sulfoximine, a glutathione-depleting agent, on the cisplatin toxicity in mice.

The effect of estrous cycle and buthionine sulfoximine on glutathione release from the in vitro perfused rat ovary.

Suggest Documents

Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine.

Oxovanadium-based inhibitors can drive redox-sensitive cytotoxicity in neuroblastoma cells and synergise strongly with buthionine sulfoximine.

Buthionine sulfoximine-induced cytostasis does not correlate with glutathione depletion.

The pro-oxidant buthionine sulfoximine (BSO) reduces tumor growth of implanted Lewis lung carcinoma in mice associated with increased protein carbonyl, tubulin abundance, and aminopeptidase activity.

Depletion of a discrete nuclear glutathione pool by oxidative stress, but not by buthionine sulfoximine. Correlation with enhanced alkylating agent cytotoxicity to human melanoma cells in vitro.

Pretreatment with buthionine sulfoximine enhanced uptake and retention of BSH in brain tumor.

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.

or buthionine sulfoximine on teratogenicity of 5-fluorouracil in mice.

The effect of in vivo glutathione depletion with buthionine sulfoximine on rat embryo development.

Heterogeneity in response to treatment with buthionine sulfoximine or interferon in human malignant glioma cells.

Effects of buthionine sulfoximine and diethyl maleate on glutathione turnover in the channel catfish.

Thermochemotherapy for B16 melanoma: combination therapy of hyperthermia, melphalan, and CCNU in mice.

Selenite-induced inhibition of colony formation by buthionine sulfoximine-sensitive and resistant cell lines.

Lens GSH depletion and electrolyte changes preceding cataracts induced by buthionine sulfoximine in suckling mice.

Interaction of buthionine sulfoximine and the stabilization of DNA-topoisomerase II complexes by doxorubicin.

Protective Effect of Tempol on Buthionine Sulfoximine-Induced Mitochondrial Impairment in Hippocampal Derived HT22 Cells.

3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.

Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion.

Enhanced in vitro cytotoxicity of 1,3-bis-(2-chloroethyl)-1-nitrosourea or buthionine sulfoximine combined with a reactive oxygen-generating enzyme immunotoxin.

Progressive modifications of mouse lens crystallins in cataracts induced by buthionine sulfoximine.

The effects of buthionine sulfoximine treatment on diaphragm contractility and SERCA pump function in adult and middle aged rats.

Danazol induces apoptosis and cytotoxicity of leukemic cells alone and in combination with purine nucleoside analogs in chronic lymphocytic leukemia.

The deleterious effect of buthionine sulfoximine, a glutathione-depleting agent, on the cisplatin toxicity in mice.

The effect of estrous cycle and buthionine sulfoximine on glutathione release from the in vitro perfused rat ovary.

Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.

Recommend Documents

Follow Us